Tina Fløyel
David Funda
Veronica I. Dodero
Martin Haupt-Jorgensen- 1Translational Type 1 Diabetes Research, Clinical Research, Steno Diabetes Center Copenhagen, Herlev, Denmark
- 2Institute of Microbiology of the Czech Academy of Sciences, v.v.i., Prague, Czechia
- 3Department of Chemistry, Organic Chemistry III, Bielefeld University, Bielefeld, Germany
- 4The Bartholin Institute, Department of Pathology, Rigshospitalet, Copenhagen, Denmark
Editorial on the Research Topic
The gut-pancreas axis in type 1 diabetes – a focus on environmental factors
The global type 1 diabetes (T1D) incidence is rising too fast to be explained by genetic drift, thereby underlining the importance of environmental factors. Drawing further attention to environmental factors as being responsible for the rising T1D incidence is the reduced occurrence of high-risk haplotypes within the HLA genes in individuals developing T1D compared to previously (1). Several environmental factors have been associated with T1D, primarily from work on the non-obese diabetic (NOD) mouse model, and some of these factors, e.g. gluten (2) and enterovirus (3), have led to human intervention trials. Many of the proposed food and microbial environmental factors can travel to the pancreatic islets from the intestinal lumen after crossing the intestinal barrier (4). In the pancreatic islets they are hypothesized to contribute to autoimmunity, e.g. via induction of beta-cell stress. Thus, the intestinal barrier function is likely of key importance. Noteworthy, intestinal permeability is increased both in pre- and clinical T1D (5), likely permitting luminal environmental factors easier entry. The present Research Topic gives an update on the involvement of environmental factors and the gut-pancreas axis in T1D.
Several of the Research Topic aspects are described in the review by Buschard, dealing with possible causes and interventions for T1D. The review discusses the involvement of the intestine in T1D. It highlights both the mucin degrading bacterium Akkermansia Muciniphila, which can decrease the intestinal permeability, and gluten, which has been shown to increase intestinal permeability via the enterocyte chemokine receptor CXCR3. Interestingly, both Akkermansia Muciniphila (6) and gluten-free diet (7) have been shown to delay diabetes development in NOD mice, pointing to future treatment targets. Regarding gluten-free diet, originally no beneficial effects were reported (8, 9), however, a more recent pilot study and a human intervention trial documented beneficial effects in new-onset T1D children (2, 10), thus more research is needed. Another theme in the review deals with beta-cell stress, which according to Buschard could mediate formation of immunogenic insulin molecules and autoimmunity. The section on sphingolipids mostly concerns sulfatide, which is both present in beta cells and nerve myelin sheets but with different functions, namely folding of insulin and facilitation of electric impulses, respectively. Interestingly, the level of sulfatide is substantially lower in individuals with new-onset T1D and could therefore be an early treatment target in T1D.
The intestinal microbiota is skewed in T1D (11) and, as discussed in the review by Buschard, the gut barrier integrity is influences by some bacteria. The original paper by Luo et al. examined the intestinal microbiota and serum metabolite composition in 49 and 52 T1D patients positive and negative for glutamic acid decarboxylase antibody (GADA+/-), respectively. The authors found that the intestinal microbiome and serum metabolite profiles differed between the GADA+/- patients. Furthermore, the abundance of the bacterial genus Alistipes was negatively associated with serum metabolites involved in tryptophan metabolism, meaning that the microbiota changes in the GADA+ T1D patients may contribute to lower tryptophan-related metabolites. This is an interesting finding, as tryptophan metabolites can bind to the aryl hydrocarbon receptor, resulting in secretion of interleukin 22, improved intestinal barrier, increased gastrointestinal motility, anti-inflammatory properties, and modulation of intestinal microbiota (12–14).
Enterovirus may be a trigger of T1D. This is primarily based on the detection of enterovirus in pancreatic islets from new-onset T1D patients (15, 16). The original article by Josefsen et al. deals with the question why 30% of the beta cells are inactive at T1D diagnosis and how they can be activated, thus relieving the stress on the active beta cells. Using DiViD and nPOD tissues, the authors analyzed gene expression levels in islets from individuals at different T1D stages. The main findings in the T1D islets were changes in genes associated with fetal dedifferentiation and asynchrony, which could explain the inactivity of the beta cells at diagnosis. The authors propose to treat T1D patients with type 2 diabetes drugs, such as GLP-1 receptor agonists and metformin, combined with anti-inflammatory compounds, to activate the inactive beta cells and prevent autoimmunity. The analyses in the article by Josefsen et al. were done on whole islets, so it is unknown which islet cell type(s) are responsible for the authors observations of modulated gene expressions. Previous studies show mixed results of treating T1D patients with GLP-1 receptor agonists (Exenatide, Albiglutide) (17–19), although a combination therapy with anti-inflammatory compounds is, to our knowledge, unexplored.
To investigate how environmental factors affect the pancreatic beta cells it is crucial with a beta-cell model that closely resembles native human beta cells. In the original article by Frørup et al. results of an in-depth characterization of the effects of pro-inflammatory cytokines on EndoC-βH5 cells are presented. This new non-proliferative beta-cell model has the advantage of being non-cancerous, free of xenotropic murine virus, and with high insulin secretion capacity. The authors report that EndoC-βH5 cells are particularly responsive to interferon-γ over other diabetogenic cytokines, which is not necessarily comparable to native human beta cells, resulting in upregulation of key cellular responses, such as MHC-I. Further studies of EndoC-βH5 cells are required, but Frørup et al. contributes with important new insights into this promising new cell model.
In conclusion, this Research Topic provides encouraging new data and hypotheses on several etiopathogenetic areas in T1D. This includes data indicating why a high percentage of beta cells are inactive at T1D diagnosis as well as microorganisms and metabolites that may play a role in intestinal barrier dysfunction in T1D. The interplay of environmental factors, followed by possible changes in the intestinal permeability and/or mucosal immune mechanisms are complex and difficult to dissect, e.g. both gut microbiota-dependent and independent dietary effects were reported in NOD mice (20, 21). Nevertheless, the underlying feature of these factors seems linked to the persistence of chronic intestinal inflammation (22). More work is needed to identify the environmental factors behind the rising T1D incidence, the time windows critical for the exposure of such factors, how they influence the intestinal barrier function, the underlying mechanisms of the elicitation of autoimmunity, and which interventions can prevent and treat T1D.
Author contributions
TF: Writing – review & editing. DF: Writing – review & editing. VD: Writing – review & editing. MH-J: Writing – original draft, Writing – review & editing.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Gillespie KM, Bain SC, Barnett AH, Bingley PJ, Christie MR, Gill GV, et al. The rising incidence of childhood type 1 diabetes and reduced contribution of high-risk HLA haplotypes. Lancet (2004) 364:1699–700. doi: 10.1016/S0140-6736(04)17357-1
2. Neuman V, Pruhova S, Kulich M, Kolouskova S, Vosahlo J, Romanova M, et al. Gluten-free diet in children with recent-onset type 1 diabetes: A 12-month intervention trial. Diabetes Obes Metab (2020) 22:866–72. doi: 10.1111/dom.13974
3. Carre A, Vecchio F, Flodstrom-Tullberg M, You S, Mallone R. Coxsackievirus and type 1 diabetes: diabetogenic mechanisms and implications for prevention. Endocr Rev (2023) 44:737–51. doi: 10.1210/endrev/bnad007
4. Bruun SW, Josefsen K, Tanassi JT, Marek A, Pedersen MH, Sidenius U, et al. Large gliadin peptides detected in the pancreas of NOD and healthy mice following oral administration. J Diabetes Res (2016) 2016:2424306. doi: 10.1155/2016/2424306
5. Bosi E, Molteni L, Radaelli MG, Folini L, Fermo I, Bazzigaluppi E, et al. Increased intestinal permeability precedes clinical onset of type 1 diabetes. Diabetologia (2006) 49:2824–7. doi: 10.1007/s00125-006-0465-3
6. Hanninen A, Toivonen R, Poysti S, Belzer C, Plovier H, Ouwerkerk JP, et al. Akkermansia muciniphila induces gut microbiota remodelling and controls islet autoimmunity in NOD mice. Gut (2018) 67:1445–53. doi: 10.1136/gutjnl-2017-314508
7. Funda DP, Kaas A, Bock T, Tlaskalova-Hogenova H, Buschard K. Gluten-free diet prevents diabetes in NOD mice. Diabetes Metab Res Rev (1999) 15:323–7. doi: 10.1002/(sici)1520-7560(199909/10)15:5<323::aid-dmrr53>3.0.co;2-p
8. Pastore MR, Bazzigaluppi E, Belloni C, Arcovio C, Bonifacio E, Bosi E. Six months of gluten-free diet do not influence autoantibody titers, but improve insulin secretion in subjects at high risk for type 1 diabetes. J Clin Endocrinol Metab (2003) 88:162–5. doi: 10.1210/jc.2002-021177
9. Fuchtenbusch M, Ziegler AG, Hummel M. Elimination of dietary gluten and development of type 1 diabetes in high risk subjects. Rev Diabetes Stud (2004) 1:39–41. doi: 10.1900/RDS.2004.1.39
10. Svensson J, Sildorf SM, Pipper CB, Kyvsgaard JN, Bojstrup J, Pociot FM, et al. Potential beneficial effects of a gluten-free diet in newly diagnosed children with type 1 diabetes: a pilot study. Springerplus (2016) 5:994. doi: 10.1186/s40064-016-2641-3
11. Abdellatif AM, Sarvetnick NE. Current understanding of the role of gut dysbiosis in type 1 diabetes. J Diabetes (2019) 11:632–44. doi: 10.1111/1753-0407.12915
12. Roager HM, Licht TR. Microbial tryptophan catabolites in health and disease. Nat Commun (2018) 9:3294. doi: 10.1038/s41467-018-05470-4
13. Dong F, Hao F, Murray IA, Smith PB, Koo I, Tindall AM, et al. Intestinal microbiota-derived tryptophan metabolites are predictive of Ah receptor activity. Gut Microbes (2020) 12:1–24. doi: 10.1080/19490976.2020.1788899
14. Monteleone I, Rizzo A, Sarra M, Sica G, Sileri P, Biancone L, et al. Aryl hydrocarbon receptor-induced signals up-regulate IL-22 production and inhibit inflammation in the gastrointestinal tract. Gastroenterology (2011) 141:237–248, 248 e231. doi: 10.1053/j.gastro.2011.04.007
15. Krogvold L, Genoni A, Puggioni A, Campani D, Richardson SJ, Flaxman CS, et al. Live enteroviruses, but not other viruses, detected in human pancreas at the onset of type 1 diabetes in the DiViD study. Diabetologia (2022) 65:2108–20. doi: 10.1007/s00125-022-05779-2
16. Krogvold L, Edwin B, Buanes T, Frisk G, Skog O, Anagandula M, et al. Detection of a low-grade enteroviral infection in the islets of langerhans of living patients newly diagnosed with type 1 diabetes. Diabetes (2015) 64:1682–7. doi: 10.2337/db14-1370
17. Pozzilli P, Bosi E, Cirkel D, Harris J, Leech N, Tinahones FJ, et al. Randomized 52-week phase 2 trial of albiglutide versus placebo in adult patients with newly diagnosed type 1 diabetes. J Clin Endocrinol Metab (2020) 105:e2192–e2206. doi: 10.1210/clinem/dgaa149
18. Herold KC, Reynolds J, Dziura J, Baidal D, Gaglia J, Gitelman SE, et al. Exenatide extended release in patients with type 1 diabetes with and without residual insulin production. Diabetes Obes Metab (2020) 22:2045–54. doi: 10.1111/dom.14121
19. Edwards K, Li X, Lingvay I. Clinical and safety outcomes with GLP-1 receptor agonists and SGLT2 inhibitors in type 1 diabetes: A real-world study. J Clin Endocrinol Metab (2023) 108:920–30. doi: 10.1210/clinem/dgac618
20. McLeod KH, Mason L, Marino E. Transplantation of fecal microbiota shaped by diet. Bio Protoc (2018) 8:e2683. doi: 10.21769/BioProtoc.2683
21. Funsten MC, Yurkovetskiy LA, Kuznetsov A, Reiman D, Hansen CHF, Senter KI, et al. Microbiota-dependent proteolysis of gluten subverts diet-mediated protection against type 1 diabetes. Cell Host Microbe (2023) 31:213–227 e219. doi: 10.1016/j.chom.2022.12.009
22. Tlaskalova-Hogenova H, Stepankova R, Tuckova L, Farre MA, Funda DP, Verdu EF, et al. Autoimmunity, immunodeficiency and mucosal infections: chronic intestinal inflammation as a sensitive indicator of immunoregulatory defects in response to normal luminal microflora. Folia Microbiol (Praha) (1998) 43:545–50. doi: 10.1007/BF02820817
Keywords: type 1 diabetes, environmental factors, gluten-free diet, enterovirus, gut-pancreas axis, NOD mouse, beta-cell stress, intestinal permeability
Citation: Fløyel T, Funda D, Dodero VI and Haupt-Jorgensen M (2023) Editorial: The gut-pancreas axis in type 1 diabetes – a focus on environmental factors. Front. Endocrinol. 14:1270297. doi: 10.3389/fendo.2023.1270297
Received: 31 July 2023; Accepted: 07 August 2023;
Published: 15 August 2023.
Edited and Reviewed by:
Jared Rutter, The University of Utah, United StatesCopyright © 2023 Fløyel, Funda, Dodero and Haupt-Jorgensen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Martin Haupt-Jorgensen, martin.haupt-joergensen@regionh.dk